Prelude Capital Management’s Global Blood Therapeutics, Inc. GBT Stock Holding History

Prelude Capital Management’s Portfolio GBT Stock Details GBT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-2,000	Closed	-$76K	–	2281
2018 Q3	$76K	Sell	2,000 -6,000	-75%	-$266K	﹤0.01%	1026
2018 Q2	$362K	Sell	8,000 -1,000	-11%	-$45.5K	0.02%	619
2018 Q1	$435K	Buy	+9,000	New	+$502K	0.03%	481
2017 Q4	–	Sell	-2,000	Closed	-$62K	–	1823
2017 Q3	$62K	Buy	+2,000	New	+$56.2K	0.01%	1039
2017 Q2	–	Sell	-1,000	Closed	-$37K	–	1938
2017 Q1	$37K	Buy	+1,000	New	+$25.2K	﹤0.01%	1128
2016 Q4	–	Sell	-1,500	Closed	-$35K	–	1857
2016 Q3	$35K	Buy	+1,500	New	+$28.6K	﹤0.01%	1168

Other funds holding GBT

BTI

Blue Trust Inc Alpharetta, Georgia $9.54B AUM 19.86% 1-Year Est. Return

HNB

Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Prelude Capital Management's GBT Position: Q4 2022 in Review

Prelude Capital Management sold out of Global Blood Therapeutics, Inc. (GBT) in Q4 2022, closing a stake of 125,029 shares — an estimated $8.51M sold.

Prelude Capital Management first reported a position in GBT in Q3 2016 and held it in 16 quarters. The position peaked at $8.51M in Q3 2022. 2 funds tracked by Wall St. Rank hold GBT as of Q4 2022.

Prelude Capital Management reported no remaining Global Blood Therapeutics, Inc. position as of Q4 2022 after selling out during the quarter.
Prelude Capital Management sold 125,029 Global Blood Therapeutics, Inc. shares in Q4 2022, an estimated $8.51M.
Prelude Capital Management first reported a position in Global Blood Therapeutics, Inc. in Q3 2016 and held it in 16 quarters.
Prelude Capital Management's Global Blood Therapeutics, Inc. position peaked at $8.51M in Q3 2022.
2 funds tracked by Wall St. Rank held Global Blood Therapeutics, Inc. as of Q4 2022.

Based on Prelude Capital Management's 13F filing for Q4 2022, filed 14 Feb 2023.